Posts by: Marta Figueiredo

Marta Figueiredo

April 18, 2022April 18, 2022

Researchers Identify Potential Antibody-based Myeloma Therapy

Researchers in Japan have identified an antibody that binds to a myeloma-specific form of a common cell surface protein, called CD98 heavy chain, and that prolongs survival when given to ... Read more

March 21, 2022March 22, 2022

Patients Have Higher COVID-19 Risk Even if Fully Vaccinated: US Study

COVID-19 News, Myeloma Research News

Even if they’re fully vaccinated, multiple myeloma patients still have an increased risk of COVID-19 infection compared with people without cancer, according to a study looking at data from more ... Read more

March 7, 2022March 7, 2022

FDA Places HPN217, Immunotherapy for Advanced Disease, on Fast Track

Myeloma Research News

The U.S. Food and Drug Administration (FDA) has given fast track designation to Harpoon Therapeutics’ HPN217 as a potential immunotherapy for people with relapsed, refractory multiple myeloma (RRMM) who have tried at least ... Read more

March 1, 2022March 1, 2022

Cilta-cel – now Carvykti – Approved by FDA for Heavily-treated Myeloma

Myeloma Research News

The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) — formerly known as cilta-cel — for certain adults with relapsed or refractory multiple ... Read more

January 24, 2022January 24, 2022

Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma

Myeloma Research News

Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three ... Read more

January 10, 2022January 10, 2022

Janssen Seeks FDA Approval of Teclistamab for RRMM

Myeloma Research News

Janssen is seeking the approval of its investigational therapy teclistamab in the U.S. for people with relapsed or refractory multiple myeloma (RRMM). “Despite all the gains that have been made ... Read more

December 20, 2021December 20, 2021

Xpovio Conditionally Approved in China for Heavily Treated Patients

Myeloma Research News

China’s National Medical Products Administration (NMPA) has conditionally approved a combination of Xpovio (selinexor) and the corticosteroid dexamethasone to treat adults with relapsed or refractory multiple myeloma (RRMM) who received ... Read more

November 15, 2021November 15, 2021

Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

Myeloma Research News

The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose ... Read more

November 8, 2021November 8, 2021

Blenrep-nirogacestat Combo Moves to Dose-testing Phase 2 of Trial

Myeloma Research News

After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test a combination of Blenrep (belantamab mafodotin) with nirogacestat in adults ... Read more

March 12, 2021March 12, 2021

Reldesemtiv Aids Motor and Respiratory Strength in Types 2 and 3, Early Trial Finds

SMA News Today

Eight weeks of treatment with investigational add-on oral therapy reldesemtiv safely improved motor and respiratory strength in adolescents and adults with spinal muscular atrophy (SMA), according to final data from a ... Read more

March 12, 2021March 12, 2021

PRX-102 Safe and Effective Once Monthly Fabry Treatment, Phase 3 Data Show

Fabry Disease News

A once-a-month regimen of the investigational enzyme replacement therapy (ERT) PRX-102 (pegunigalsidase alfa) is safe and effective at maintaining disease stability in adults with Fabry disease, top-line data from the ... Read more

March 11, 2021March 11, 2021

Amylyx Planning to Ask Health Canada to Approve AMX0035 to Treat ALS

ALS News Today

Amylyx Pharmaceuticals plans to soon apply to Health Canada, requesting approval of oral AMX0035 to treat amyotrophic lateral sclerosis (ALS) based on the findings of the CENTAUR clinical trial. The company ... Read more

March 11, 2021March 11, 2021

Metabolic Disorders May Underlie Some Diagnosed Autism Cases

Sanfilippo News

Genetic metabolic diseases, such as Sanfilippo syndrome, may underlie an autism spectrum disorder (ASD) diagnosis, especially when accompanied with additional symptoms, according to a case series in Turkey. The data ... Read more

March 10, 2021March 10, 2021

Roctavian, Potential Hemophilia A Gene Therapy, Get Fresh FDA Support

Hemophilia News Today

The U.S. Food and Drug Administration (FDA) has given regenerative medicine advanced therapy (RMAT) designation to Roctavian, an investigational gene therapy by BioMarin Pharmaceutical for severe hemophilia A. The designation is “a ... Read more

March 10, 2021March 10, 2021

Zolgensma Available Soon to Eligible SMA Type 1 Patients in England, Scotland

COVID-19 News, SMA News Today

The gene therapy Zolgensma was added to the list of medications available to eligible spinal muscular atrophy (SMA) type 1 patients through England’s and Scotland’s national health services (NHS). With a ... Read more